Drug Trial Radar · NCT05573464
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
559
Actual
Start
Sep 27, 2022
Primary completion
Mar 26, 2024
Study completion Mar 26, 2024
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 12-week (with an extension to 52 weeks in a subset of participants) study comparing the safety of BGF MDI HFO twice daily (BID) with BGF MDI HFA BID in participants with moderate to very severe COPD.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
BGF MDI HFO 320/14.4/9.6 μgDrug
Budesonide, Glycopyrronium, and Formoterol Fumarate
BGF MDI HFA 320/14.4/9.6 μgDrug
Budesonide, Glycopyrronium, and Formoterol Fumarate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Percentage of Participants With Serious Adverse EventsTime frame: Over 12 weeks
- Number and Percentage of Participants With Serious Adverse EventsTime frame: Over 52 weeks
- Number and Percentage of Participants With Non-serious Adverse Events >5%Time frame: Over 12 weeks
- Number and Percentage of Participants With Non-serious Adverse Events >5%Time frame: Over 52 weeks
- Number and Percentage of Participants With Adverse Events of Special InterestTime frame: Over 12 weeks
- Number and Percentage of Participants With Adverse Events of Special InterestTime frame: Over 52 weeks
Locations
91 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
Newport Beach, California
Research Site
Miami, Florida
Research Site
Sarasota, Florida
Research Site
Tampa, Florida
Research Site
Valparaiso, Indiana
Research Site
Crowley, Louisiana
Research Site
North Dartmouth, Massachusetts
Research Site
St Louis, Missouri
Research Site
Charlotte, North Carolina
Research Site
Wilmington, North Carolina
Research Site
Dublin, Ohio
Research Site
Grants Pass, Oregon
Research Site
Portland, Oregon
Research Site
Anderson, South Carolina
Research Site
Columbia, South Carolina
Research Site
Gaffney, South Carolina
Research Site
Longview, Texas
Research Site
McKinney, Texas
Research Site
Richmond, Virginia
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Quilmes, Argentina
Research Site
Rosario, Argentina
Research Site
San Fernando, Argentina
Research Site
Blagoevgrad, Bulgaria
Research Site
Dupnitsa, Bulgaria
Research Site
Lom, Bulgaria
Research Site
Pernik, Bulgaria
Research Site
Sandanski, Bulgaria
Research Site
Sevlievo, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Veliko Tarnovo, Bulgaria
Research Site
Vidin, Bulgaria
Research Site
Truro, Nova Scotia, Canada
Research Site
Ajax, Ontario, Canada
Research Site
Burlington, Ontario, Canada
Research Site
Guelph, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.